BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol Med 2021:S1471-4914(21)00154-4. [PMID: 34229973 DOI: 10.1016/j.molmed.2021.06.007] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S, Zhu S. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-022-02460-8] [Reference Citation Analysis]
2 Yu R, Zhong J, Zhou Q, Ren W, Liu Z, Bian Y. Kaempferol prevents angiogenesis of rat intestinal microvascular endothelial cells induced by LPS and TNF-α via inhibiting VEGF/Akt/p38 signaling pathways and maintaining gut-vascular barrier integrity. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.110135] [Reference Citation Analysis]
3 Li X, Li Q, Xiong B, Chen H, Wang X, Zhang D. Discoidin domain receptor 1(DDR1) promote intestinal barrier disruption in Ulcerative Colitis through tight junction proteins degradation and epithelium apoptosis. Pharmacol Res 2022;183:106368. [PMID: 35905891 DOI: 10.1016/j.phrs.2022.106368] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cifarelli V, Peche VS, Abumrad N. Vascular and lymphatic regulation of gastrointestinal function and disease risk. Biochim Biophys Acta Mol Cell Biol Lipids 2022;:159207. [PMID: 35882297 DOI: 10.1016/j.bbalip.2022.159207] [Reference Citation Analysis]
5 Wang Y, Hong C, Wu Z, Li S, Xia Y, Liang Y, He X, Xiao X, Tang W. Resveratrol in Intestinal Health and Disease: Focusing on Intestinal Barrier. Front Nutr 2022;9:848400. [DOI: 10.3389/fnut.2022.848400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lian S, Liu J, Wu Y, Xia P, Zhu G. Bacterial and Viral Co-Infection in the Intestine: Competition Scenario and Their Effect on Host Immunity. Int J Mol Sci 2022;23:2311. [PMID: 35216425 DOI: 10.3390/ijms23042311] [Reference Citation Analysis]
7 Han MN, Finkelstein DI, Mcquade RM, Diwakarla S. Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics. JPM 2022;12:144. [DOI: 10.3390/jpm12020144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Long X, Liu D, Gao Q, Ni J, Qian L, Ni Y, Fang Q, Jia W, Li H. Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. Front Endocrinol (Lausanne) 2021;12:773340. [PMID: 35035378 DOI: 10.3389/fendo.2021.773340] [Reference Citation Analysis]
9 Matsubara Y, Kiyohara H, Teratani T, Mikami Y, Kanai T. Organ and brain crosstalk: The liver-brain axis in gastrointestinal, liver, and pancreatic diseases. Neuropharmacology 2021;205:108915. [PMID: 34919906 DOI: 10.1016/j.neuropharm.2021.108915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
10 Hu Y, Li C, Hou Y. Possible regulation of liver glycogen structure through the gut-liver axis by resistant starch: a review. Food Funct 2021;12:11154-64. [PMID: 34694313 DOI: 10.1039/d1fo02416g] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Gao W, Zhu Y, Ye J, Chu H. Gut non-bacterial microbiota contributing to alcohol-associated liver disease. Gut Microbes 2021;13:1984122. [PMID: 34711112 DOI: 10.1080/19490976.2021.1984122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]